1. Home
  2. ICHR vs PVLA Comparison

ICHR vs PVLA Comparison

Compare ICHR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$96.71

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$139.66

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICHR
PVLA
Founded
1999
2015
Country
United States
United States
Employees
N/A
29
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
ICHR
PVLA
Price
$96.71
$139.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
15
Target Price
$49.50
$171.87
AVG Volume (30 Days)
1.3M
328.6K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$947,652,000.00
N/A
Revenue This Year
$20.51
N/A
Revenue Next Year
$17.08
$104,350.18
P/E Ratio
N/A
N/A
Revenue Growth
11.61
N/A
52 Week Low
$13.15
$24.07
52 Week High
$113.58
$161.38

Technical Indicators

Market Signals
Indicator
ICHR
PVLA
Relative Strength Index (RSI) 56.53 58.32
Support Level $60.40 $106.07
Resistance Level N/A $151.18
Average True Range (ATR) 8.36 9.55
MACD 0.41 2.75
Stochastic Oscillator 38.66 58.26

Price Performance

Historical Comparison
ICHR
PVLA

About ICHR Ichor Holdings

Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: